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A FIVE YEAR RETROSPECTIVE STUDY OF TUBERCULOSIS AT A PUBLIC 
HOSPITAL IN THE ECUADORIAN HIGHLANDS. 
Eric G. Shmookler, Peter A. Selwyn, and Patrick O'Connor. Department of Internal 
Medicine, Yale University, School of Medicine, New Haven, CT. 
ABSTRACT: This study focuses on the challenges facing tuberculosis (TB) control 
programs in developing nations such as Ecuador. METHODS: Through a 
retrospective chart review investigating a largely indigenous, Quechua-speaking 
population at a public hospital in rural Ecuador, we analyzed characteristics of all 
known TB cases and evaluated risk factors for non-completion of TB treatment in this 
population.. RESULTS: Of the 192 patients in this study with active TB, 64.1% 
were male, the average patient age was 35.15 (± 18.52) years, 21.4% had a prior 
history of tuberculosis treatment, the average distance between patient residence and 
the hospital was 9.9 (± 11.5) kilometers, and 57.9% of patients lived in the mountains 
above 3000 meters. 42.2% of patients failed to complete treatment. Statistical 
analysis showed the following to be significant risk factors for non-completion of 
treatment: a) prior treatment for tuberculosis, (OR 3.03; p=0.032); b) increased 
patient age (p=0.035); c) living over 3000 meters, (OR 1.96; p=0.031); and d) 
increased distance between patient residence and the hospital (p=0.0007). Neither 
patient gender nor disease site (pulmonary versus extrapulmonary) were significant 
risk factors. CONCLUSIONS: Developing nations such as Ecuador face unique 
public health problems related to limited infrastructure, difficult terrain, poverty, and 
lack of education regarding tuberculosis. Efforts designed specifically for this 
environment must be employed to improve identification and effective treatment of 
infectious patients. Such efforts could include improved clinical evaluation of 
symptomatic patients, consistent use of sputum analysis in diagnosis, incorporation of 
cultural, linguistic, organizational, and pharmacological changes to make treatment 
more successful and accessible, use of incentives to keep patients in treatment, and 
improved outreach programs which take advantage of the existing local infrastructure 
to identify infectious patients, contact patients who abandon treatment, and ideally, 
establish an effective program of directly observed therapy. 
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PREFACE: 
This document reviews tuberculosis as a persistent, worldwide public health 
problem, but focuses on the particular challenges facing TB control programs in 
developing nations such as Ecuador. Specifically, this thesis investigates the problems 
surrounding the identification of smear-positive pulmonary TB patients and the 
successful implementation of treatment regimens in the setting of an indigenous, 
Quechua-speaking population of the Ecuadorian Andes. 
This thesis begins by reviewing the epidemiology of tuberculosis, including a 
worldwide overview, an introduction to Latin America, and a discussion of tuberculosis 
in Ecuador. This report then reviews the general principles of TB transmission, 
pathogenesis, diagnosis, treatment, and (multi-)drug resistant disease. 
After reviewing the general principles of tuberculosis, this paper will address the 
challenges of TB control programs in developing countries. Through a retrospective chart 
review investigating patients treated at a public hospital in rural Ecuador, this thesis will 
explore the population risk factors and demographic variables statistically associated with 
successful completion of TB treatment. The conclusion will discuss the many factors 
contributing to proper identification of patients and completion of treatment, taking into 
account the complex economic, cultural, linguistic, technological, and medical problems 
which confront TB control programs in developing nations like Ecuador. 
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INTRODUCTION 
EPIDEMIOLOGY 
Tuberculosis (TB), a chronic bacterial infection caused by the bacillus 
Mycobacterium tuberculosis, is a leading cause of worldwide morbidity and mortality. 
The World Health Organization (WHO) estimates that over one-third of the world’s 
population is infected with TB, and the disease is responsible for six percent of all deaths 
worldwide. WHO figures from the early 1990’s disclose that globally there were over 30 
million cases of active TB, over 10 million new cases of TB annually, and more than 3 
million TB deaths per year. ’ ■ 
In industrialized nations the incidence of TB fell for many decades during the 
20th century, assisted by improvements in nutrition and housing, the use of basic public 
health measures such as education, isolation, and quarantine, as well as the introduction 
of antibiotics in 1946. In the early 1900’s, TB was the leading cause of death in the 
United States (U.S.).4 Beginning with the introduction of isoniazid in 1953, the total 
number of TB cases in the U.S. declined an average of 5.0% annually up until 1984 
(84,304 cases in 1953 fell to 22,255 in 1984),5 despite exponential population growth. 
However, in 1985 (approximately when AIDS appeared) this trend reversed and the case 
rate began to increase. In the six years from 1985 to 1991, the number of cases in the 
United States increased 18.0 percent.6 Many urban centers were particularly afflicted; the 
case rate in New York City (NYC) increased 30.4% during the same period (1985 to 
1990).7 
TB commonly strikes low income, underprivileged communities and minorities, 
including the homeless, intravenous (IV) drug users, alcoholics, EIIV-positive 
individuals, recent immigrants from countries with high rates of TB, residents of long¬ 
term care facilities such as prisons and psychiatric institutes, and contacts of patients with 
active (especially pulmonary or laryngeal) TB. At present, more than two-thirds of 
Americans with active TB are minorities. Compared with whites, the risk of TB is five 
times higher among Hispanics and Native Americans, eight times higher among Afro- 
Americans, and ten times higher among Asian-Americans. In 1994 in central Harlem (a 
poor, minority community), the incidence of new cases of TB was ten times above the 

3 
o 
U.S. average (9.4 new cases per 100,000 nationally versus 90.7 per 100,000 in Harlem). 
However, it is worth noting that nearly a third of TB cases in the U.S. now occur among 
middle and upper income groups, despite the popular belief that TB predominantly 
affects the poor. 9’10 

LATIN AMERICA: 
In Latin America* today, TB poses one of the major public health problems. In 
1995, approximately 400,000 cases were reported (including extrapulmonary TB) in 
Latin America and the Caribbean1; in 1994, there were 222,596 reported cases. In 1995 
alone, over 75,000 people in Latin America and the Caribbean died of tuberculosis. In 
this part of the world, 1,100 people develop TB disease and 200 people die from it 
daily.11 The true incidence of TB may be 500,000 cases annually, as PAHO (Pan- 
American Health Organization) estimates that at least a third of local cases are not 
reported. 
1986 1987 1988 1989 1990 1991 1992 1993 1994 
FIGURE 1: Incidence of tuberculosis in Ecuador. 1986 to 1994. Figures are nationwide and 
indicate all forms of tuberculosis separately, as well as the total for all forms combined. For 
reference, the TB case rate in the United States was 8.7 cases per 100,000 inhabitants in 1995, 
about ten times lower than the Ecuadorian case rate in 1994 (86.1 per 100,000). Statistics for 
non-confirmed pulmonary tuberculosis (yellow triangles) are unavailable prior to 1991. Source: 
Carrera AP. El Programa de Control de la Tuberculosis en el Ecuador. Revista de la Pontificia 
Universidad Catolica del Ecuador. Quito, 1996. 
From 1981 to 1986, tuberculosis was the seventh (7th) most common cause of 
death in Ecuador. Figure 1 shows that from 1986 through 1994, the situation nationally 
has not improved. However, it is important to note that the increase in the total number 
In this document, the term "Latin America" refers to Central and South America, including Brazil, but 
excluding the islands of the Caribbean. 
^ For epidemiological purposes, the WHO combines Latin America and the Caribbean into a single 
geographical unit. 
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of TB cases may in part be an artifact resulting from the addition of "Non-confirmed" 
data beginning in 1991 (yellow triangles). 
In Ecuador, the annual risk of infection is estimated at 1.5%. From 1990 to 1994, 
the reported number of cases of bacteriologically confirmed pulmonary TB increased 
39%, with an average annual increase of 9.75% (see Figures 1 and 2). During the same 
four year period, the reported number of pulmonary TB cases (including “non- 
confirmed” cases-- those never supported by microscopic identification of acid fast 
bacteria in sputum) increased 90% from 4808 cases in 1990 to 9167 cases in 1994.13 
According to local physicians these official statistics seriously under-report the number 
of Ecuadorian TB cases, due to incomplete notification, diagnostic errors, and the 
confusion of other pulmonary diseases with pulmonary tuberculosis.14 
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FIGURE 2: Annual number of reported tuberculosis cases (including extrapulmonary TB) 
in three regions of Ecuador, 1990 to 1995. The figures for Ecuador show the official trend 
nationwide. Figures for the “Sierras” reflect reported cases in the Andes highlands, where the 
Native American population is concentrated. Imbabura province figures indicate reported case 
numbers for a region containing only 2.5% of the nation’s population. Source: National 
statistics, from Dr. Luis Flor Freire, Director, Tuberculosis Control Program, Quito, Ecuador. 
According to World Health Organization’s (WHO) recent figures (1994), Ecuador 
remains one of nine countries in Latin America with an “extremely severe” case rate 
(over 85.0 new cases per year per 100,000 individuals). The other countries are Haiti, the 
Dominican Republic, Paraguay, Bolivia, Peru, El Salvador, Guatemala, and Honduras.15 
TB is especially likely to be under-reported among the (Native-American) indigenous 
- 
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communities due to their lack of access to the state healthcare apparatus and its statistical 
bodies.16 
Due to a combination of environmental, social, biological, and cultural factors, 
TB infection rates and mortality rates worldwide remain highest among poor 
communities with little access to modem health care.17 According to PAHO, the 
worldwide TB pandemic is facilitated by an aging population, inadequate investment in 
public health resources especially in poor countries (in Ecuador, spending on health care 
as a percentage of GDP has never been lower), huge numbers living in poverty, increased 
1 R 
global travel, immigration, and the HIV pandemic. 
OUECHUA-SPEAKING POPULATION IN THE HIGHLANDS OF ECUADOR: 
While in recent years the AIDS epidemic has dramatically changed the 
epidemiologic profile of tuberculosis in industrialized nations, TB remains largely 
associated with extreme poverty in developing nations such as Ecuador. Ecuador, the 
second smallest nation by land area in South America, has a population of just over 12 
million19, a Gross Domestic Product (GDP) of just US 1,310 dollars per capita and an 
estimated 63% of households living in severe poverty (1994 figures).*' In 1993, national 
unemployment was 14.0% of the working-age population, and under-employment was 
50%. The Ecuadorian government defines “working-age” as those over eight (8) years of 
age.21 In 1990 the minimum wage was US$ 65 per month.22 
In 1990, Ecuador spent US $ 79 per person on health care (in 1988 dollars); that 
year, the United States spent US $ 2,763 per person on health care (1988 dollars).23 In 
1993, the Ecuadorian budget for health was 4.0% of the national budget, as compared to 
7.6% in 1990.24 In three years (1990 to 1993), spending on health care decreased 47.4% 
(as a percentage of the total government spending). 
The Andes Mountains of South America—which include Ecuador—are home to 
the largest population of Quechua-speaking Native Americans in the world. Over 10 
million people today speak Quechua, the most common indigenous language in the 
Western Hemisphere. Called “Runasimi” (“the Mouth of the People”), Quechua 
originated thousands of years ago in what is today south central Peru. It became the 
official language of the “Tawantinsuyu” (the ancient Incan Empire)— an elaborate and 
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sophisticated society spanning what today are Ecuador, Peru, Bolivia, the northern half of 
Chile, and northwestern Argentina. Since the 16th century, Quechua has been written 
phonetically using the Roman alphabet (for example, “Please help me!” could be written 
“Allichu yanaparqokuway!”). Originally, however, Quechua was written using a 
complex of knotted cords, called “khipu”, capable of recording all the information 
necessary to support the highly organized administration of Incan society." 
Quechuan society became marginalized after the Spanish conquest of 1532, and 
the language was outlawed by the Spanish following the great Incan revolt of Tupaq 
Amaru II in 1780. Nevertheless, its use spread, but mostly at the expense of lesser-used 
indigenous languages such as Aymara. Quechua today is threatened by Spanish, which 
remains the only official language in all the Andean nations (except for Peru, which 
recognized Quechua in 1975). Quechua today receives no official recognition by the 
Ecuadorian government, meaning that health educational materials are unavailable in this 
commonly spoken language and that members of this community have less access to 
information and medical care than their Spanish-speaking ("mestizo") counterparts. 
The lack of rural medical facilities has contributed to TB recurrence rates that are 
much higher among Quechua-speakers than in the general population27 and has not only 
facilitated the spread of tuberculosis among this population, but also encouraged the 
development of (multi-) drug resistant disease. Since the indigenous population 
constitutes one of the poorest segments of Ecuadorian society, it is not surprising to find a 
higher incidence of TB in this group than in the population as a whole. In 1992, for 
example, the annual TB mortality rate among Quechua-speaking Ecuadorians was 26.0 
per 100,000 inhabitants, while the rate for the country as a whole was only 12.4 per 
100,000 inhabitants. Similarly, in the same year, the TB incidence (infection) rate among 
Quechuans was over 400 new cases per 100,000 inhabitants, while the rate for the entire 
nation was less than half, at 191 per 100,000. For comparison, the TB case rate for 
central Harlem in 1990 was 200 per 100,000, and this rate was about four times higher 
90 
than the New York City average and 20 times higher than the national U.S. rate. 
Pulmonary diseases (including TB) are the single leading cause of death in 
Imbabura province (a province with one of the largest concentrations of Quechua- 
speakers in Ecuador). These diseases kill more Imbabura residents annually than motor 
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vehicle accidents, cancer, and all forms of heart disease combined. In 1990 (the last year 
for which figures are available), the mortality rate for pulmonary diseases was 168.7 per 
100,000 rural inhabitants of Imbabura province. 30 In order to approximate the 
prevalence of Mycobacterium Tuberculosis among symptomatic members of the 
indigenous population in Imbabura, I cite an investigation performed by the Institute of 
Medical Technology in Peguche, near Otavalo, in which 252 sputum samples were 
examined from 241 symptomatic (i.e.: coughing) members of the indigenous community 
of Peguche. Standard Ziehl-Neelson staining and microscopic examination revealed 65 
smear-positive results (25.8%).31 
The concentration of health professionals in Ecuador remains low, especially in 
rural areas (nationally there are 11.1 physicians per 10,000 Ecuadorians, while rural 
Imbabura province has just 4.3 physicians per 10,000 people). The entire province of 
Imbabura has only 303 public hospital beds (about one per 1000 people). Over 91% of 
health care professionals are concentrated in the urban centers of Quito and Guayaquil, 
with just 9% responsible for the rest of the country. This means that in order to seek 
high quality medical care, many patients must travel considerable distances to unfamiliar 
cities. Aside from the psychological barriers to undertaking such journeys, these voyages 
mean lost work and lost income, especially for the men who are generally employed as 
migrant workers in agriculture or basic construction. Volunteering in the emergency 
room at the hospital in Otavalo which is the site of the retrospective tuberculosis 
investigation that follows, I witnessed the lack of basic medication and medical supplies 
(including needles, syringes, gloves, and suture material—many of which were reused on 
multiple patients instead of discarded). Patients must purchase all basic supplies from 
private pharmacies and return to the hospital to have them applied/injected. 
To clarify misconceptions and stereotypes concerning the Quechua-speaking 
population of the highlands (“Sierras”), gain greater understanding of the health-related 
issues facing this community, and identify unique challenges faced by health workers in 
this environment, I interviewed local patients, consulted independent anthropologic and 
sociologic investigations, and reviewed official census data. According to the most 
recent census data (1990), the province of Imbabura has a population of over 265,500 
inhabitants, roughly equally divided between urban centers (with 129,174 inhabitants) 
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such as Ibarra, Otavalo, and Cotacachi, and rural farmland (with 136,325).34 This rugged 
province remains home to the Quechua-speaking Native South Americans (direct Incan 
descendants who currently span a mountainous belt through Colombia, Ecuador, Peru, 
and Bolivia) and-- in Ecuador-- are centered around the 4000 year old Indian marketplace 
of Otavalo. The distinctive lifestyle and traditions of the people living in Imbabura lend a 
highly unique flavor to the region, but also promote conditions favoring the persistence 
and transmission of TB and other diseases. 
To provide a visual image, over three-quarters (77%) of rural houses are 
constructed with clay-tiled roofs, 56% have walls of adobe (clay), and 57% have floors of 
packed earth. Over two-thirds of rural households cook over a wood fire (“a lena”), and a 
third of rural inhabitants sleep in rooms with five or more inhabitants.35 This last figure 
is particularly relevant to TB transmission, since those sharing a bedroom with an 
individual with active pulmonary TB have approximately a 60% annual risk of becoming 
infected themselves.36 
A 1992 survey concluded that among rural households of Imbabura, 50% have 
access to clean water, 40% have systems for sewage or trash disposal, and 30% have 
latrines. For urban households of Imbabura, these figures are significantly higher: 85% 
enjoy potable water, 90% sewage disposal, and 70% have latrines.37 
Furthermore, official rates of (Spanish language) literacy remain low, especially 
among rural women: 81.6% of rural men can read and write while only 67.5% of rural 
io 
women can do so. Just over half (54%) of rural households have electricity , meaning 
that refrigeration is limited and television is not widespread— restricting public health 
educational efforts to radio instead of TV. 
When indigenous TB patients were asked what they believed caused their 
pulmonary disease, the unusual responses stress the importance of spiritualism and 
mysticism in this unique community and the lack of education regarding TB and the 
transmission of infectious diseases. KAP (Knowledge, Attitude, and Practice) surveys 
show that a majority of rural indigenous patients believe their symptoms to be the result 
of either breathing bad air (“mal aire”) or supernatural powers (“mal ojo”~ “evil eye”).39 
“Mai aire” is a common diagnosis by local curanderos (traditional healers) in which 
passing through areas where angry spirits reside (forests, river forks, water springs, or 

10 
cemeteries) causes constitutional distress including headache, nausea, vomiting, fatigue, 
and diarrhea. “Mai ojo,” caused by the malicious gaze of a person possessed by evil 
spirits, is prevented by wearing protective medallions, crucifixes, or brightly colored 
clothing (anything that distracts the attention of the possessed and prevents eye contact 
with the victim). The crucifix is a legacy from the Spanish conquistadors and the 
majority of the indigenous population in Ecuador remains Catholic. 
Local curanderos treat these disorders by performing a cleansing (“limpieza"), in 
which the victim is covered with raw eggs, garlic, and herbs, or smeared with the carcass 
of a sacrificed guinea pig. The dead animal absorbs the diseased elements from the 
patient’s body, leaving them cured. In addition, concentrated alcoholic beverages 
(“aguardiente”) impart magical powers, visions, and prevent spirits from harming 
individuals.40 
These local traditions, dubious to the Western scientific mind, exemplify the 
marriage of medicine, spiritualism, and religion in indigenous, Andean culture. These 
communities suffer high rates of infant mortality (44.0 per 1000 live births in 1995 in 
Ecuador as a whole).41 Only 18% of rural births occur in a clinic, and only 7% of rural 
women receive prenatal care.42 Quechua-speaking Ecuadorians have an average life 
expectancy at birth of 44 years (compared with 69 in Ecuador as a whole and 76 in the 
United States).43 
The examples above stress the cultural barriers encountered in attempting to treat 
members of this community with modem medical protocols, and the cultural obstacles 
which must be addressed in designing effective health interventions and educational 
materials. 
PATHOGENESIS AND CLINICAL ASPECTS: 
Spread person to person via tiny respiratory droplets (1-5 microns in diameter), 
the TB bacillus is dispersed and suspended in the air when an individual with 
inadequately treated pulmonary or laryngeal TB coughs, sneezes, speaks, sings, or 
laughs.44 Patients most likely to be infectious are: 1) those with untreated pulmonary or 
laryngeal TB who are actively coughing; 2) patients undergoing cough-inducing 
procedures; 3) patients with positive sputum smears; 4) and those with radiographic 
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lesions of the chest suggesting tuberculosis. Treated patients usually become smear 
negative after 2 months of chemotherapy and are much less likely to transmit disease than 
untreated patients. Without treatment, 50% of patients with active TB die within five 
years of disease onset. On average, in one year, a person with infectious (pulmonary or 
laryngeal) TB infects 10 to 15 others (depending on coughing activity and living 
conditions).45 This suggests that in five years, the average untreated person with active 
infectious TB infects 50 to 75 other healthy individuals before they succumb to their own 
disease; this stresses the importance of early identification of infectious patients and 
immediate initiation of appropriate chemotherapy. Haphazard or intermittent 
chemotherapy worsens the epidemiologic milieu, by prolonging the lives of infectious 
patients and allowing them to infect others while not curing them. Fortunately, most 
patients become noninfectious within two weeks after starting appropriate 
chemotherapy;46 in contrast, patients receiving chemotherapy frequently remain 
infectious if the duration of treatment, combination of drugs, or dosages are inadequate. 
Tuberculosis has two stages: latent TB (“infection”), and active TB (“disease”). 
The majority of healthy people who become infected with Mycobacterium tuberculosis 
never develop clinically active disease since the normal immune system effectively 
suppresses the infection. Once they become infected, healthy (immunocompetent) 
individuals have just a 5%-10% risk of developing TB disease during their lifetimes.47 
Such persons with latent TB (TB infection) do become PPD positive, but remain free of 
symptoms, show no X-ray evidence of disease, and are not contagious. Latent TB persists 
for many years— sometimes for life— and clinical disease may develop at any time after 
infection, especially if the host subsequently becomes immunocompromised. 
Immunocompromised individuals (i.e. patients with AIDS) have a 5%-10% annual risk of 
progressing from latent to active tuberculosis, once infected with TB. HIV-infected 
patients are 30 times more likely to develop active TB once infected, and in 1995, 5% of 
TB cases in Latin America were associated with HIV coinfection.49 The introduction and 
spread of the human immunodeficiency virus (HIV) among impoverished populations 
can logarithmically increase the rate of tuberculosis.50 
Official figures claim that the incidence of AIDS remains much lower in Ecuador 
than in the United States. In 1994, the annual incidence of new AIDS cases (per million 
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inhabitants) was 245.7 in the U.S. and only 10.4 in Ecuador.51 However, in an officially 
catholic country like Ecuador where AIDS patients are often cruelly stigmatized, the 
likelihood of reporting bias distorting official figures is high. At any rate, given the lack 
of AIDS related education, the church’s prohibition of condom use, the frequency with 
which needles, syringes, and sutures are re-used on multiple patients, and the growing 
intravenous drug problem in Quito and Guayaquil, the incidence of new AIDS cases in 
Ecuador may rise quickly in the future. 
TB, although most commonly affecting the lungs, can cause multi-systemic 
disseminated disease and, when inadequately managed, is frequently fatal. Generally 
speaking, active pulmonary TB is characterized by cough, often productive with bloody 
streaks (hemoptysis) lasting two weeks or longer accompanied by chest discomfort, 
profound fatigue, fever, night sweats, chills, weight loss, and anorexia. Tragically, the 
vast majority of TB morbidity and mortality is preventable, and the disease generally 
debilitates victims during the most productive years of their lives (25-54 years old). In the 
absence of effective therapy, pulmonary TB pursues a progressive course with chronic 
wasting and, often, death. Overall, the death rate for untreated pulmonary tuberculosis is 
60%.53 
Microscopic examination of sputum samples to identify acid fast bacilli (“smear 
analysis”) is a commonly used, cost-effective bacteriologic method of identifying those 
patients who are most infectious and thus— from a public health perspective— most 
urgently in need of treatment. In many industrialized nations including the United States 
[where the BCG (Bacillus Calmette-Guerin) vaccine is not routinely used], infected 
persons can be easily identified by a positive skin reaction following intradermally 
injection of a purified protein derivative (PPD). In many developing countries including 
Ecuador, however, due to widespread vaccination of infants with the BCG vaccine 
(which causes recipients to react positively to the PPD), screening with the PPD is 
considered difficult to interpret and is not widely used as a diagnostic tool in Ecuador.* 
While the PPD is frequently used as a diagnostic tool in the United States— even in patients who have 
been previously vaccinated with the BCG vaccine- the most recent (1993) protocol published by the 
Ecuadorian Ministry of Health states that the PPD has "limited clinical value" in BCG recipients. The 
PPD is not frequently used as a diagnostic tool in Ecuador. 
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While the BCG vaccine is widely used in Ecuador in infants less than one year of 
age (officially coverage ranges between 85% and 99% from 1981 to the present)54, its 
utility is more to prevent the development of the most severe disseminated forms of TB 
and tuberculous meningitis than to control the spread of pulmonary TB within the general 
population. BCG, an attenuated strain of M. bovis administered to over 2 billion people 
worldwide, is considered safe but its effectiveness remains uncertain. 
In developing countries, the World Health Organization (WHO) recommends 
sputum smear examination as the most cost-effective method to identify those patients 
with the highest priority for receiving TB chemotherapy. As sputum smear analysis 
identifies those pulmonary TB patients who harbor the highest mycobacterial load in their 
lungs and upper respiratory tract, it identifies those patients who are most infectious. 
Thus, sputum smear analysis (“baciliscopia” in Spanish) provides the most appropriate 
tool to diagnose pulmonary TB in Ecuador. 
Inadequate use of sputum smear examinations remains very common and 
provides problems for both treatment and diagnosis. Patients with respiratoiy symptoms 
are frequently started on TB medication without laboratory confirmation of their 
diagnosis. Obtaining a sputum sample is feared as a dangerous procedure for the health 
care personnel assigned to the task. TB patients are most contagious when actively 
coughing, as providing a sputum sample generally encourages. No masks or other 
protective mechanisms (i.e. isolation rooms or ventilation) are available. (In fact, in my 
experience, opening a hospital window for ventilation can evoke furious responses, since 
patients and staff alike believe that cold air / breezes aggravate pulmonary disease.) Lack 
of protection discourages staff from obtaining the sputum samples which would confirm 
diagnosis and assist in treatment decision-making. Financial restrictions are largely 
responsible for these limitations. 
Mycobacterium tuberculosis antibiotic resistance develops in response to 
inadequate or improper use of antitubercular medications, and can be extremely difficult 
(and expensive) to treat. To prevent the selection of TB drug-resistant mutant strains 
(present naturally in small numbers), monotherapy in patients with active TB disease 
must be strictly avoided and at least two effective drugs must always be administered 
simultaneously. Due to the long generation time and extended periods of metabolic 
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inactivity that characterize Mycobacteria, prolonged courses of chemotherapy are always 
required. Pulmonary and extrapulmonary tuberculosis are treated similarly. 
A variety of drug regimens are currently utilized to treat tuberculosis, differing in 
drug combination and duration of treatment depending on whether the patient has been 
treated for TB in the past or shows evidence of drug resistance. Isoniazid, rifampin, 
streptomycin, pyrazinamide, and ethambutol are the most commonly used, and regimens 
range from 6 months to over one year in duration. 
The 1992 recommendations of the American Thoracic Society (ATS) state: 
“The preferred regimen for treatment of [new cases of] active TB 
includes an initial course of daily isoniazid, rifampin, and pyrazinamide 
for two months (the induction phase), followed by a continuation phase 
of daily isoniazid and rifampin for four months, for a total duration of 
six months. Ethambutol or streptomycin must be included in the initial 
regimen until drug susceptibility studies are available, unless there is 
little possibility of primary resistance.”55 
In 1989 the Ecuadorian Ministry of Public Health adopted a three-drug “short 
course” treatment regimen— similar to that recommended by the ATS. The regimen is 
deficient in five important ways. Isoniazid and rifampin are given only twice weekly 
(instead of every day) during the four-month continuation phase.56 Second, since 
susceptibility testing is not available and drug-resistance is common (a 1995 study 
showed that 44% of samples were resistant to at least one drug57), either ethambutol or 
streptomycin should be included during the initial two months. Third, many patients are 
treated with the same “short course” regimen regardless of their treatment history. Many 
patients who failed treatment numerous times in the past are once again started on the 
same six-month regimen with the same three drugs. Fourth, the dosages are generally not 
personalized according to patient weight; patients weighing less that 30 kg receive the 
same dosage as those weighing more than 80 kg. Lastly, it proved very difficult to secure 
the political support necessary to modify the official treatment regimens in favor of more 
effective treatment protocols. 
TREATMENT COMPLETION AND DRUG RESISTANCE 
A major problem in TB treatment is patient default (abandoning treatment 
prematurely against medical advice). Default rates of 40 to 60% are common, and in 
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some circumstances are much higher. In one survey of 105 patients in Imbabura 
province, 71.3% failed to take their medication as directed.59 As expected, default rates 
are highest in parts of the world where endemic TB is coupled with limited resources. In 
previous years, much effort was spent trying to identify demographic groups most likely 
to fail to comply with their prescribed treatment. Such efforts have been abandoned in 
favor of universal supervision, as it was concluded that neither age, sex, religion, 
education, race, nor socioeconomic status reliably predicted rates of compliance.60 
Highly successful treatment programs in the United States focused on increasing 
compliance in all patients. This is achieved by shortening the duration of treatment, 
using twice or thrice weekly dosing when possible, closely monitoring patients for 
adverse effects of medications, educating patients, providing all drugs and services free 
of charge, utilizing directly observed therapy, and offering incentives for patients to 
remain in treatment (including bus or transit tokens, food coupons, clothing, cash, and 
social services such as housing, government benefits, and child care arrangements).61 
Directly observed therapy (DOT) is defined as the observation by a responsible health 
care worker as the TB patient ingests anti-tubercular medications.62 Following the 
implementation of an aggressive program of DOT in New York City, the incidence of TB 
fell 21% in just two years (1992 to 1994).63 In a 13 year study comparing 407 patients 
who did not receive DOT with 581 patients who did, direct supervision reduced the rate 
of acquired resistance (where the patient’s initially drug-sensitive disease became 
resistant, probably due to inadequate chemotherapy) from 14.0 to 2.1%, decreased the 
relapse rate from 20.9% to 5.5%, and lowered the number of antibiotic resistant relapses 
from 25 to 5.64 
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Patients abandoning treatment prematurely remain a major problem in Ecuador. 
Table 1 lists the rates of patients completing treatment in Ecuador as a whole, according 
to official statistics.65 
YEAR TUBERCULOSIS PATIENTS COMPLETING TREATMENT Sample Size 
1987 27.0 % n=3209 
1991 82.0 % n=4679 
1993 56.0 % n=5648 
1994 53.0 % n=9685 
TABLE 1: Percentage of Tuberculosis Patients Completing Chemotherapy in Four 
Different Years, 1987 to 1994. Patients who “complete chemotherapy” are those who picked up 
their TB medication from the hospital every week for the full six months. Since no staff exists to 
observe patients (DOT), and sputum samples are not regularly analyzed to confirm sputum 
conversion, rates of non-compliance may be much higher than reflected in these official figures. 
Source: Official statistics from Dr. Luis Flor Freire, Tuberculosis Control Program, Quito, 
Ecuador. 
Figure 3 (below) illustrates the treatment outcome for those patients who initiated 
tuberculosis treatment (abbreviated TX) in Ecuador during 1993.66 
FIGURE 3: Treatment Outcome for Tuberculosis Patients Nationwide, 1993. Follow-up 
data is not available for the 16% of patients who transferred to another health center; therefore, 
“transferred” may belong with “abandoned treatment.”. Source: Official statistics provided 
by Dr. Luis Flor Freire, Tuberculosis Control Program, Quito, Ecuador. 
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Various studies identify cultural, sociologic and economic factors that cause 
especially high default rates among the Quechua-speaking population of Ecuador. These 
include malnutrition, extreme poverty, high rates of alcoholism, lack of access to health 
care and health educational materials, and employment as migrant workers (which 
requires frequent travel). In addition, lack of primary school education, lack of education 
regarding tuberculosis, the negative stigma of having TB, adverse side effects of TB 
medication (nausea, vomiting, abdominal pain, etc.), expense and inconvenience of 
frequent travel to the hospital to receive medication, long waiting periods, poor hospital 
service and organization, irregular hospital hours, as well as pursuing alternative 
treatment from "curanderos" or "hierberos" (traditional healers) provided further risk 
factors for patients abandoning chemotherapeutic treatment prematurely. 
There are two forms of TB resistance: primary and secondary. In primary 
resistance, the patient is infected with bacilli that are already resistant to one or more 
antibiotics. The transformation and selection of previously susceptible Mycobacteria 
characterize secondary resistance (also called acquired resistance), which is most 
/o 
commonly due to improper use of antibiotics. 
Antibiotic monotherapy rapidly leads to in vitro resistance and clinical treatment 
failure.69 The development of effective anti-tubercular drug regimens in the 1960’s 
caused a shift in treatment strategy, dramatically increasing the percentage of patients 
treated as outpatients. While reducing the need for expensive hospitalization, this change 
had deleterious effects on patient compliance that manifested themselves as treatment 
failure and the selection of (multi-) drug resistant strains. In fact, the prevalence of drug- 
resistant TB among U.S. patients with pulmonary TB increased steadily for three decades 
from 2% to 9% (from 1954 to 1984).70 In New York City by 1991, 33% of all TB cases 
were resistant to at least one drug71. 
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Figure 4 lists the frequency of TB drug resistance following the evaluation of 
sputum cultures from 110 Ecuadorian TB patients.72 
DRUG PERCENT OF SAMPLES RESISTANT 
RIFAMPIN 19.5% 
ISONIAZID 18.0% 
STREPTOMYCIN 12.0% 
ETHAMBUTOL 12.0% 
RIFAMPIN + ISONIAZID 8.1 % 
RIFAMPIN + ISONIAZID + ETHAMBUTOL 0.0 % 
ISONIAZID RIFAMPIN STREPTOMYCIN ETHAMBUTOL ISONIAZID + ISONIAZID + 
RIFAMPIN RIFAMPIN + 
ETHAMBUTOL 
FIGURE 4: Rates of Antibiotic Resistance among 110 Patients Treated for Tuberculosis in 
Ecuador, 1993. Note the multi-drug resistant samples (8.1%), considered difficult to treat even 
in developed countries. Source: Informe del Laboratorio de Tuberculosis— Porcentaje de 
Cultivos Resistentes. (Tuberculosis Laboratory Report— Percentage of Resistant Cultures). 
Publication of the Hospital “Vozandes del Oriente”, Ecuador, 1989-1993. 
In a separate study of 1019 patients in Quito, Ecuador from 1995, 44% were 
resistant to at least one anti-tubercular drug. Thus, antibiotic resistance provides a 
significant obstacle for TB treatment and control programs in Ecuador. 
Poor management on the part of physicians, patient non-compliance, the 
worldwide HIV epidemic, and a lack of funding and interest in treating tuberculosis 
contribute to increased treatment failure and higher drug resistance in general. In 
Ecuador in particular, several practices and inadequate resources facilitate the selection 
and distribution of drug resistant strains of Mycobacterium tuberculosis. The majority of 
patients are rarely (if ever) observed taking their medications, despite strict regulations to 
the contrary (see translation of Ecuadorian Manual below). Patients stop taking their 
medications prematurely after just a month or two of treatment when begin to feel better 
(symptomatic improvement often occurs after 2 to 3 weeks of treatment). Third, 
unavailability (and poor distribution) of TB drugs forces patients to interrupt treatment or 
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continue treatment with only one or two available drugs. Sputum smear examinations are 
rarely used to monitor treatment progress and success, causing many patients to falsely 
believe they have been treated successfully. In a study from Ibarra, the largest city in 
Imbabura province, from 1992, 99.04% of patients were not followed with sputum 
examinations.74 TB culture and sensitivity testing are rarely available, causing many 
patients with primary resistant disease to go unrecognized and receive inappropriate 
treatment regimens. Sixth, resources are inadequate to evaluate contacts of identified 
infectious individuals and to adequately rule out TB in patients with respiratory 
symptoms (i.e. hemoptysis) who present to local clinics. Public laboratories for sputum 
smear analysis are poorly staffed, and unreliable, and anti-TB drugs are widely sold 
without prescriptions in thousands of pharmacies throughout the country promoting the 
misuse of these medications or their uncontrolled introduction into the environment. 
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HYPOTHESES AND SPECIFIC AIMS: 
This research investigates recorded cases of TB at the medium-sized (50 bed) 
Hospital "San Luis" of Otavalo (HSLO). The HSLO, located in the Canton Otavalo of 
Imbabura province, is one of three public hospitals serving a unique, predominantly 
(>95%) indigenous Quechua-speaking Native-American community. As a relatively 
poor province with modest political influence and a large indigenous population, 
conditions in this hospital are representative of the many marginalized and impoverished 
communities of the Andean highlands. 
Distinguished by cultural, socioeconomic, and linguistic differences, indigenous 
(Quechua-speaking) Ecuadorians are at risk for receiving inadequate healthcare from the 
state hospitals. Many members of the indigenous community speak only the Quechua 
language (especially women, who work on small plots of land, raising children and 
tending crops and animals, while the men travel to work on construction or industrial / 
agricultural projects). Quechua enjoys no official recognition, and members of this 
community are often extremely poor and may remain excluded from the Spanish- 
language educational, health and social services provided by the government. While 
statistics are published regarding the number of TB cases in each province, official 
statistics do not divide patients based on ethnicity or socioeconomic indicators, and it is 
difficult to infer information about the indigenous community from official statistics. 
This is a retrospective chart review of 192 patients who received TB treatment 
between February 1991 and April 1996 at the small, public, Hospital "San Luis" of 
Otavalo— located at about 2500 meters above sea level in the Andes highlands of 
Ecuador. Reviewing all inpatient and outpatient tuberculosis records, this investigation 
will study the mechanics of patient diagnosis and treatment, and identify the statistical 
relationship between completion of antitubercular therapy and epidemiologic and 
demographic variables. 
I 
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The following represent the specific aims of this study: 
1. To identify the extent to which sputum smear and culture analysis were utilized 
in the diagnosis of tuberculosis, 
2. To describe TB treatment completion rates among patients with active TB at the 
Hospital "San Luis" of Otavalo for the five-year period between February 1991 
and April 1996, 
3. To determine specific risk factors and demographic characteristics associated 
with non-completion of therapy, 
4. To develop strategies for improving TB control in developing countries such as 
the setting of this study. 
In particular, the following hypotheses were evaluated: 
1. At least one-third of patients in this retrospective study will have a history of 
prior treatment for tuberculosis. 
2. At least one-third of patients will never have received laboratory confirmation 
(i.e. positive sputum smear analysis) of their disease. 
3. At least one-third of patients in this retrospective study will not have completed 
the prescribed six-month treatment regimen for tuberculosis. 
4. In the study group, there exists a statistically significant association between 
abandoning treatment prematurely and: 
a) patient age 
b) patient gender, 
c) pulmonary versus extrapulmonary disease, 
d) prior history of TB treatment, 
e) increased distance between patient residence and the Otavalo hospital, or 
f) residence in the mountainous highlands (over 3000 meters) poorly served 
by public transportation. 
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METHODOLOGY: 
This retrospective study reviewed the written medical records of 192 patients who 
initiated TB chemotherapy between February 10, 1991 and April 25, 1996 at the Hospital 
"San Luis" in Otavalo, Ecuador, In the 192 patient charts reviewed, patients fell into one 
of three categories: patients with pulmonary TB who received sputum smear analysis that 
confirmed their diagnosis (hereafter referred to as cases of “confirmed pulmonary TB”), 
patients with a clinical presentation suggesting pulmonary TB who never received 
sputum smear analysis or were smear negative but still presented with clinical evidence 
of pulmonary TB, such as hemoptysis, cough lasting more than 3 weeks, fatigue, weight 
loss, night sweats, fever, shortness of breath, and chest pain (hereafter called cases of 
“non-confirmed pulmonary TB”), and patients treated for "extrapulmonary TB". The 
diagnosis of "extrapulmonary TB" was based on a clinical examination by a physician 
who, after examining the pleura, lymphatic ganglia, joints, urinary tract, nervous system 
(meningeal TB), or gastrointestinal tract arrived at a clinical diagnosis of extrapulmonary 
TB. Fluid cultures were not available to confirm the diagnosis of extrapulmonary TB. 
Specimens for culture and sensitivity analysis must be sent to Quito for processing and, 
in practice, are not used in the diagnosis of TB in patients at the HSLO. Sputum smear 
analyses were prepared and interpreted at the on-site laboratory of the Hospital "San 
Luis". Since both "non-confirmed pulmonary" cases and "extrapulmonary cases" were 
based exclusively on clinical judgement, there exists the possibility of some overlap 
between these two diagnostic groups. 
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TREATMENT REGIMEN: 
All 192 patients with active TB were prescribed a six-month antibiotic treatment 
regimen divided into two distinct phases: the Initial Phase and the Consolidation Phase. 
The details of these treatment phases are as follows: 
Initial Phase - Three (3) oral medications administered six (6) days a week for a 
duration of eight weeks: 
1) isoniazid, 300 milligrams daily (Monday through Saturday, Sunday 
excluded) 
2) rifampin, 600 milligrams daily (Monday through Saturday, Sunday 
excluded) 
3) pyrazinamide, 1500 milligrams daily (Monday through Saturday, Sunday 
excluded) 
Consolidation Phase - After completing the initial phase, patients receive two (2) oral 
medications administered twice per week (i.e. Monday and Thursday, or 
Tuesday and Friday) for a duration of 16 weeks: 
1) isoniazid, 900 milligrams twice a week. 
2) rifampin, 600 milligrams twice a week. 
As far as resources permitted, TB patients in this study were treated in accordance 
with the Manual of Rules, Procedures, and Protocols for the Control of Tuberculosis, an 
outline introduced in 1989 by the National Tuberculosis Control Program (a division of 
the Ecuadorian Ministry of Public Health).78 Patients received treatment for the first two 
weeks as inpatients at the hospital in Otavalo under the direct supervision of medical 
personnel. While inpatients, neither isolation rooms, ventilation systems, nor air- 
filtration mechanisms were available to prevent the nosocomial spread of tuberculosis. 
After 14 days, patients were discharged to the care of their families and referred to 
outpatient services, where they were instructed to continue outpatient TB chemotherapy 
for an additional duration of 22 weeks. Patients were not required to pay for their 
antibiotic TB medications nor the medical consultations or services they received at the 
The Manual of Rules, Procedures, and Protocols for the Control of Tuberculosis fails to provide an 
explanation for excluding the Sunday dose of antibiotics during the Initial Phase. Most internationally 
accepted regimens for TB chemotherapy recommend administration of antibiotics 7 (seven) days a 
week, at least during the first eight weeks (the Initial Phase). One local physician suggested that a 
respite one day per week may prevent hepatic toxicity in patients already suffering from severe 
malnutrition, while not impairing the efficacy of the treatment regimen. I was unable to independently 
verify this theory. 
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HSLO; by law, treatment for tuberculosis is provided free of charge. However, vitamin 
B6 was not provided to patients receiving the above regimen. 
As outpatients, all individuals in the study group were required to visit the 
hospital once a week to retrieve the subsequent week’s TB medication. The hospital is 
located in downtown Otavalo, approximately 15 minutes by foot from the local bus 
terminal. Otavalo is served by a network of public buses, which provide essentially the 
only form of local public transportation. Private ownership of motor vehicles is 
uncommon, and the vast majority of local residents rely on public transportation. The 
outpatient TB clinic at the hospital in Otavalo dispensed medication only during the 
afternoon, Monday through Friday, from 1 p.m. until 4 p.m. local time. 
SELECTION OF STUDY SAMPLE 
The 192 patients in this study represent all known cases of active tuberculosis 
who started treatment at the Hospital "San Luis" in Otavalo between February 10, 1991 
and April 25, 1996. Medical records for patients who began treatment at the HSLO prior 
to and after the above mentioned dates were unavailable. All inpatient and outpatient 
medical records for HSLO patients were reviewed and only those patients who began TB 
chemotherapy for an explicit diagnosis of active TB (pulmonary or extrapulmonary) were 
included in the study sample. Patient contacts who received TB chemoprophylaxis (six 
months of isoniazid alone) were excluded from this study sample. To the best of our 
knowledge, this study sample represents 100% coverage of patients treated for active TB 
at this site during these dates, for whom records were present in the record room. All 
charts were reviewed by a single reviewer (ES) and information was abstracted and 
recorded on a standardized data entry sheet. 
Particular emphasis was placed on locating all records for patients treated for 
active tuberculosis. However, conversations with local medical staff raised the 
possibility that an unknown subset of patient records could have been transferred or 
otherwise misplaced. The possibility of such detection bias is recognized and this study 
cannot quantify the extent to which local patients with tuberculosis were not identified by 
the hospital, or received additional treatment at another hospital other than the HSLO. 
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DATA COLLECTION: 
Nursing staff recorded each patient’s visit to the outpatient clinic on the patient’s 
treatment card; if patients neglected to pick up their medication for four consecutive 
weeks, they were classified as having abandoned treatment. DOT was not provided on 
days that patients picked-up their medication at the hospital. If patients re-presented after 
abandoning treatment, they were reinitiated in the treatment regimen starting from the 
initial phase. 
Outpatient records indicate only whether patients received their medication for 
each subsequent week. Since DOT (directly observed therapy) was not available, these 
records do not directly indicate that patients ingested the allotted medications as 
prescribed. The HSLO patient records used in this retrospective study do not show that a 
patient definitely completed a treatment regimen, but they do reliably identify those 
patients who abandoned treatment. If a patient did not arrive at the hospital to receive 
their medications, then it is safe to presume that they did not ingest those medications. 
HSLO records include a clinical history and physical examination, diagnostic 
information and the results of laboratory examinations. The history contributes 
demographic data including gender, age, residence, previous history of TB treatment, and 
treatment outcome. 
The variables extracted from the patient charts and described below are: 
1. Patient age, 
2. Patient gender, 
3. Distance between patient residence and the hospital (in kilometers, measuring 
travel distance using local topographical maps), 
4. Whether patients live in the isolated mountains surrounding Otavalo (above 3000 
meters in elevation), 
5. Whether patients began treatment for : confirmed pulmonary TB, 
: non-conflrmed pulmonary TB, 
: extrapulmonary tuberculosis, or 
6. Whether patients had received TB treatment in the past, 
7. Whether patients abandoned treatment. 
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DATA ANALYSIS: 
Center for Disease Control (CDC) public-access epidemiology software was used 
for univariate and multivariate statistical analysis. This provided variable frequency, 
mean, median, mode, variance, standard deviation, odds ratios (OR), maximum 
likelihood estimates (MLE), and risk ratios (RR). The outcome of interest in this analysis 
was those patients who did not complete the prescribed treatment regimen outlined 
above. In data analysis, we determined demographic characteristics of the sample, and 
the prevalence of different demographic and clinical features. We subsequently 
identified those patients who completed treatment and those who failed to complete the 
treatment regimen; the definition of treatment non-completion was the failure of a 
patient to pick-up their weekly supply of antibiotics at the hospital outpatient clinic for 
four consecutive weeks. These two groups were compared using a case-control format to 
determine the risk factors associated with completion or non-completion of treatment. 
Bivariate and multivariate analysis was performed to identify any statistically 
significant association between a negative treatment outcome (i.e. not completing 
treatment) and the above-mentioned variables. Uncorrected, Mantel-Haenszel, and Yates 
corrected Chi-square analysis was used to evaluate categorical variables. The ANOVA 
student's t-test (for normally distributed data) and the Kruskal-Wallis H (Mann-Whitney 
or Wilcoxon Two-Sample Test) were used to evaluate the difference in means for 
continuous variables. Confidence intervals (95 percent) were calculated using the exact 
method. Bartlett's test was used to evaluate homogeneity of variance. 
Multivariate analysis (using stratification) was performed to control for 
confounding variables and evaluate effect modification. Testing for interaction assumed 
a multiplicative model, and Mantel-Haenszel weighted (adjusted) odds ratios were used 
where appropriate to compensate for confounding due to extraneous variables. 
Confounding was identified by comparing Crude and (Mantel-Haenszel) adjusted odds 
ratios. Effect modification was identified by comparing odds ratio of each stratum, and 
was tested statistically using Woolfs chi-square. All statistical analysis was performed 
with Epi-Info version 6.04b (USD Inc., Stone Mountain, Ga.). 
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RESULTS 
PATIENT DIAGNOSIS: 
In this retrospective sample, 179 out of 192 patients were treated for pulmonary 
TB (93.2%). The remaining 13 patients (6.8%) were treated for extrapulmonary TB. 
There were zero reported cases of tuberculosis meningitis at the HSLO during the five- 
year study period. Patients were divided into three possible diagnostic groups: 
1. "confirmed" pulmonary TB patients (123 patients — 64% of total patients), 
2. "non-confirmed" pulmonary TB patients (56 patients — 29% of total patients), and 
3. extrapulmonary TB patients (13 patients - representing 6.8% of the total). 
"Confirmed" cases of pulmonary TB were verified by laboratory sputum smear 
examination. "Non-confirmed" cases of pulmonary TB were diagnosed clinically but 
never confirmed by microscopic sputum smear analysis. Of all patients in this 
retrospective sample treated for pulmonary tuberculosis, 56 of 179 patients (31.3%)— or 
slightly less than a third — never received laboratory confirmation of their diagnosis of 
pulmonary TB. In addition, of the 192 patients treated for active TB at this hospital 
during this five-year period, zero patients received culture or antibiotic sensitivity 
analysis. 
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PATIENT CHARACTERISTICS AND TREATMENT OUTCOME: 
A total of 192 patients were treated for active tuberculosis at the Hospital "San 
Luis" of Otavalo between February 10, 1991 and April 25, 1996. 
DIAGNOSTIC CATEGORY 
Patient Confirmed Non-Confirmed Extrapulmonary ALL PATIENTS 
Characteristic_Pulmonary # (%) Pulmonary # (%) TB # (%)_# (%)_ 
Abandoned Treatment 
Completed Treatment 
45 / 123 (37%) 
78 / 123 (63%) 
28 / 56 (50%) 
28 / 56 (50%) 
8/13 (62%) 
5 / 13 (38%) 
81 / 192 (42%) 
111 / 192 (58%) 
Male Patients 
Female Patients 
82/ 123 (67%) 
41 / 123 (33%) 
34/56 (61%) 
22 / 56 (39%) 
7/13 (54%) 
6/13 (46%) 
123 / 192 (64%) 
69/ 192 (36%) 
No Prior History of TB Treatment. 
Patients With Prior TB Treatment. 
99/ 123 (80%) 
24/ 123 (20%) 
42 / 56 (75%) 
14 / 56 (25%) 
10/13 (77%) 
3/13(23%) 
151 / 192 (79%) 
41/192 (21%) 
Reside Below 3000 Meters* 
Reside Above 3000 Meters 
56/ 114(49%) 
58/114(51%) 
15 /52 (29%) 
37 /52 (71%) 
4/12(33%) 
8/12 (67%) 
75 / 178 (42%) 
103 / 178 (58%) 
Mean Patient AgeA 
Mean Distance From Flospital* 
33.85 ± 18.40 yrs 
9.29 ± 12.81 kms 
35.80 ± 18.53 yrs 
10.96 ± 9.92 kms 
44.69 ± 18.37 yrs 
9.42 ± 6.99 kms 
35.15 ± 18.52 yrs 
9.89 ± 11.47 kms 
TABLE 2: Patient Characteristics Divided by Specific Diagnosis. The final column shows 
summary data for all 192 TB patients treated during the five year period at the HSLO. Almost 
two-thirds of patients were male and only a small minority (7%) were treated for extrapulmonary 
disease. Over a fifth of patients (21%) had received prior TB treatment. All figures are based on 
written medical records of the HSLO. Abbreviations: yrs= years; kms= kilometers. 
* 178 out of 192 total patients (93%) indicated their place of residence. 
A Figures for "Mean patient age" and "Mean distance from hospital" are expressed as the mean ± 
standard deviation. 
As detailed in Table 2 above, male patients (123 men comprising 64.1% of the 
total) outnumbered female patients (69 women, making up 35.9% of total) almost two to 
one. Over a fifth of patients (21.4%) had a history of prior treatment for tuberculosis at 
the Hospital "San Luis" of Otavalo, while the majority (78.6%) had no documented 
history of antitubercular treatment. However, some patients classified as having "no prior 
history of TB treatment" may have received treatment for TB at another institution 
without this treatment being recorded in the local medical records. 

29 
FIGURE 5: Age Distribution. Mean patient age is 35.153, standard deviation ± 18.52 years. 
Median was 31.0, Mode: 28.0, Range: 1-77 years. 
The average patient age was 35.15 years with a standard deviation of 18.52 years. 
Overall, male patients were slightly younger with an average age of 34.24 (+/- 17.94) 
years, while female patients were slightly older with an average age of 36.85 (+/- 19.58). 
While women in this study were an average of 2.6 years older than the men, this 
difference was not statistically significant (p=0.35). 

30 
FIGURE 6: Travel Distance (kilometers) from Patient Residence to Hospital in Otavalo. 
178 out of 192 patients (93%) reported their place of residence (n=184). The mean distance was 
9.891 km with a SD of ±11.473 km; Median distance was 8.0 km; Mode was 1.0 km; Range: 1 
to 65 km. 
Patients lived an average of 9.9 kilometers from the hospital (standard deviation: 
± 11.5 km). Divided by gender, male patients lived an average of 8.86 (± 10.48) 
kilometers from the hospital, while female patients had to travel an average of 2.70 
kilometers farther, living an average of 11.56 (± 13.61) km from the hospital. This 
difference in mean distances from the hospital, however, was not statistically significant 
(p=0.29). The majority of patients (57.9%) lived at an altitude above 3000 meters, and 
the remaining 42.1% lived in the more accessible valleys below 3000 meters. 
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FACTORS PREDICTING NON-COMPLETION OF TREATMENT: 
Of 192 patients, 81 patients (42.2%) failed to pick up their medication for four or 
more consecutive weeks and, by definition, were considered to have abandoned 
treatment. 
Not 
Comoletine Treatment 
(n=81) 
Comoletine 
Treatment 
(n=l11) 
o-values 
Odds 
Ratios 
Average Age (± SD) 38.6 years (± 18.9) 32.6 years (± 17.9) p=0,035* N/A 
Average Km to Hospital 13.2 km (± 14.9) 7.3 km (± 7.6) p=0.0007* N/A 
Percent (%) Male 71.6 % 58.6 % p=0.063 1.78 
% w/ Prior TB Treatment 32.1 % 13.5 % p=0.032* 3.03 
% Living over 3000 meters 67.1 % 51.0 % p=0.031* 1.96 
% w/ Extrapulmonary TB 9.9 % 4.5 % p=0.241 2.32 
TABLE 3: Characteristics of Patients who Completed Treatment versus characteristics of 
Patients who Did Not Complete Treatment. All Patients (n=192) initiated treatment for active 
tuberculosis during a five-year period at the Hospital "San Luis" of Otavalo, Ecuador. 
* statistically significant with p < 0.05 
SD: Standard Deviation 
km: kilometers 
N/A: not applicable 
Bivariate statistical analysis (summarized in Table 3 above) revealed a 
statistically significant relationship between abandoning treatment prematurely and: 
1. a history of prior treatment for tuberculosis, Odds Ratio=3.03, (p=0.032), and 
2. residing in the mountains, at an altitude over 3000 meters, Odds Ratio=1.96, 
(p=0.031) 
In addition, comparing the difference in means (ANOVA) between patients who 
abandoned treatment and those who did not abandon treatment revealed a statistically 
significant relationship between abandoning treatment and: 
1. increased patient age; patients who abandoned treatment were an average of 6.0 years 
older (p=0.035), and 
2. increased distance between patient's home and the hospital; patients who abandoned 
treatment lived an average of 5.9 kilometers farther from the hospital (p=0.0007). 
Of the male patients, 60 out of 127 patients (47.2%) abandoned treatment, while 
of the female patients, only 26 out of 73 patients (35.6%) abandoned treatment. 
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However, the influence of patient gender in abandoning treatment was not found to be 
statistically significant (p=0.063). 
B Did Not Complete Treatment □ Completed Treatment 
All patients combined Confirmed pulmonary Non-Confirmed Extrapulmonary 
TB patients pulmonary TB tuberculosis 
FIGURE 7: Percent (%) of Patients in the Study Group who Completed or Did Not 
Complete Treatment for Tuberculosis. Data is shown for all patients in the study group 
combined, and for patients divided by specific diagnosis. Numbers indicate the actual number of 
patients in each group. Note that only 13 patients in this study group were diagnosed with 
extrapulmonary tuberculosis. 
Figure 7 above shows that, of the 123 patients treated for confirmed pulmonary 
TB, 45 patients (36.6%), 95%CI [28.1 %-45.7%] abandoned treatment. Of patients with 
non-confirmed pulmonary TB, 28 out of 56 individuals abandoned treatment (50.0%), 
95%CI [36.3%-63.7%], Examining just the extrapulmonaiy TB patients, 8 patients out of 
13 abandoned treatment (61.5%), 95%CI [31.6%-86.1 %]. In sum, 81 patients (42.2%) 
abandoned treatment. While patients diagnosed with extrapulmonary TB apparently had 
the highest rate of abandoning treatment (61.5%), the statistical relationship between 
abandoning treatment prematurely and patient diagnosis was not statistically significant 
(p=0.241). 
On multivariate analysis, other variables were considered as possible confounding 
factors. Patient gender, while not an important confounding factor (Crude OR=1.96; 
adjusted OR=2.01), did reveal remarkable effect modification for abandoning treatment 
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in patients who live in the mountains (above 3000 meters). Female patients living in the 
mountains were seven times as likely (OR=7.0; 1.56 to 35.90) to not complete treatment 
as female patients not living in the mountains. Men living in the mountains, on the other 
hand, were just 1.3 times as likely to abandon treatment as men not living in the 
mountains 
Prior treatment for tuberculosis demonstrated a similar effect in high altitude 
patients who abandoned treatment. For patients who lived in the mountains, those with a 
history of prior TB treatment had an OR of 9.43 (95%CI: 1.63 to 62.23) while those 
without a history of prior treatment had an OR of just 1.46 (95%CI: 0.67 to 3.19). Thus, 
patients living in the mountains who had a prior history of TB treatment were apparently 
much more likely to abandon treatment than those in the mountains who had never 
received prior treatment for tuberculosis. 
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DISCUSSION 
This investigation utilized a retrospective chart review of all the (192) 
tuberculosis patients who began TB treatment at the public hospital in Imbabura province 
(Ecuador) between February 1991 and April 1996. This was performed to investigate the 
problems surrounding the identification of active TB cases and the successful 
implementation of treatment regimens in the setting of an indigenous, Quechua-speaking 
population of the Ecuadorian Andes. The final result of this research was to identify the 
population risk factors and demographic variables significantly associated with non¬ 
completion of TB treatment in this patient population. 
Tuberculosis, one of the most common notifiable infectious diseases and a 
principal cause of morbidity and mortality worldwide, remains a major public health 
problem in both developing and industrialized nations. However, the number of patients 
involved and specific populations affected vary greatly between industrialized and 
developing nations. In industrialized nations, TB commonly affects elderly patients 
suffering from endogenous reactivation of past infection and only a small percentage of 
new cases result from recent infection. In developing nations, in contrast, the risk of TB 
infection is high and the disease spans all age groups. 
The study of TB in developing nations is particularly important because the vast 
majority of TB patients reside in the developing world. In 1990, 7.6 million (95%) of 
active TB cases occurred in developing countries, while 400,000 cases (5%) were located 
in the industrialized world. Due to limited resources and unique epidemiologic and 
demographic profiles, developing nations also face public health problems which are 
different from those affecting wealthier nations. The HIV pandemic poses especially 
difficult problems for TB epidemiology in many of the poorest developing nations. 
Worldwide, over 3 million individuals are dually infected with both HIV and 
Mycobacterium tuberculosis and HIV infection is the single risk factor most commonly 
associated with activation of latent TB infection. However, 2.4 million (80%) of these 
dually infected patients live in Sub-Saharan Africa, indicating that this problem is much 
more concentrated in some parts of the developing world than in others. HIV will no 
doubt pose an increasingly important public health problem in Latin America as well, but 
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at present this problem is most concentrated in Sub-Saharan Africa and only 5% of 
worldwide cases of TB are currently associated with HIV infection.79 
In developing nations, while TB infection is frequently common in the 
community, treatment programs are encouraged to focus their efforts on patients with 
sputum smear-positive disease— since these are the patients most likely to infect others. 
Most developing nations simply cannot afford to provide chemoprophylaxis to contacts 
OA 
or to asymptomatic, PPD positive patients. In addition, many developing countries face 
higher rates of drug-resistance due to the poor past performance of TB control programs 
and the uncontrolled private sector use of antibiotics. Thus, national TB control 
programs in developing and industrialized countries face different epidemiologic 
problems and often receive contrasting recommendations for TB case-finding and 
treatment. 
In all countries, effective TB control efforts can be divided into case detection and 
treatment. The WHO recommends BCG vaccination at birth, and case-finding and 
treatment with priority given to patients with smear-positive infectious disease. As 
mentioned previously, BCG vaccination prevents morbidity and mortality associated with 
the most severe forms of childhood TB, but the epidemiological impact of mass BCG 
vaccination has been limited. In the majority of developing nations, the actual 
implementation of the WHO's case-detection and treatment strategy has been poor. 
In the future, enzyme linked immunosorbant (ELISA) assays or DNA probes for 
mycobacterial DNA or RNA may provide inexpensive new diagnostic tools to allow 
more widespread screening in developing nations. At present, however, passive case 
detection (the screening and diagnosis of only those patients who present to healthcare 
providers with signs and symptoms suggestive of TB) remains the recommended method 
of case-finding in developing countries. The WHO strives for target coverage (the ability 
to detect cases of active tuberculosis) of 60-65% in low income countries with poorly 
developed transport and communications, and 85% in middle-income countries with 
relatively well-developed infrastructure. A 65% case-finding coverage rate has recently 
been achieved in Tanzania , suggesting that higher coverage rates are feasible in other 
developing nations (such as Latin America) and especially in countries with more 
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resources and better infrastructure. The WHO global target by the year 2000 is 70% 
82 
coverage. 
CASE DETECTION: USE OF SPUTUM SMEAR AND CULTURE ANALYSIS: 
Ecuador as a whole has an incidence of tuberculosis of about 86.1 new cases per 
100,000 inhabitants.83 The most recent (1990) census indicates that the patient 
population served by the Hospital "San Luis" of Otavalo is 265,000, and this population 
has certainly grown since 1990. An approximation based on this TB incidence in this 
population suggests an average of about 228 new cases of TB per year. During the five- 
year span of medical records reviewed by this retrospective study at the Hospital "San 
Luis", we can approximate (228 x 5) 1140 new cases of active TB in this geographic 
population. The fact that only 192 patients were treated for tuberculosis during five years 
at the Hospital "San Luis" of Otavalo suggests a coverage (case-finding) rate of 16.8% 
(192 out of an estimated 1140 patients entered treatment). This estimate may be 
conservative since it assumes that the incidence of TB is the same among the largely 
Quechua-speaking population of Imbabura province as it is in the rest of Ecuador. 
However, as discussed previously, data indicate an incidence for TB that is significantly 
higher among the indigenous (Quechua-speaking) population that among the 
(Ecuadorian) population as a whole. On the other hand, some patients from this region 
may have traveled to Ibarra or Quito to seek medical treatment for tuberculosis and 
therefore may not be included in the records of the Hospital "San Luis". In 1990, the 
O A 
WHO estimated worldwide coverage for tuberculosis of 46%, and this figure remains 
significantly higher than the estimated coverage at the Hospital "San Luis" in Otavalo of 
16.8%. 
Many factors may contribute to the low case-finding rate by the Hospital "San 
Luis". This region is largely populated by Quechua-speaking Native South Americans 
and the hospital employs only one Quechua-speaking healthcare worker to facilitate the 
care of patients in this community who do not speak Spanish. In addition, the local 
reputation of the hospital is not excellent, and many patients view the hospital as a 
resource of “last resort”. Patients with financial resources frequently travel to Ibarra or 
Quito for what they perceive as higher quality care, and the community around Otavalo 
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pursues a deeply entrenched tradition of non-Westem and spiritual medicine which may 
prevent patients from seeking care at this hospital. 
Patients with "non-confirmed" pulmonary tuberculosis never received a 
microscopic sputum smear examination— due to a lack of hospital resources, standards, 
or the reluctance of hospital staff to elicit a sputum sample from a patient with presumed 
pulmonary TB. Patients are most contagious when actively coughing, as providing a 
sputum sample generally demands. No masks or other protective mechanisms (i.e. 
isolation rooms or ventilation) are available at the majority of public Ecuadorian hospitals 
(including the hospital in Otavalo). Lack of protection discourages staff from obtaining 
sputum samples which would both confirm diagnosis, so that patients who do not have 
TB are not initiated on a treatment regimen inappropriately, and also help demonstrate 
treatment effectiveness by providing a standard to documenting sputum smear 
conversions. 
However, some patients with "non-confirmed" pulmonary TB submitted sputum 
samples which were interpreted as smear negative by laboratory personnel. In these 
patients, the attending physician elected— on clinical grounds based on the presence of 
signs and symptoms including cough lasting more than three weeks, hemoptysis, fever, 
weight loss, night sweats, shortness of breath, and chest pain— to pursue treatment for 
pulmonary tuberculosis. From 1991 to 1996, zero sputum cultures or sensitivity analyses 
were performed for patients in this study group even though nationwide studies showed 
TB drug resistance to be common (see Introduction). Sputum culture and antibiotic 
sensitivity analyses were not available at the Hospital "San Luis" of Otavalo. All TB 
patients at this hospital were treated with the same triple drug antibiotic regimen 
(isoniazid, rifampicin, and pyrazinamide) regardless of their treatment history. 
Internationally accepted treatment protocols recommend at least four drugs and five 
drugs for patients with suspected or confirmed drug-resistant disease. At present, these 
regimens are only available to the small minority in Ecuador with the financial resources 
to seek private care and pay for these regimens themselves. 
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TREATMENT COMPLETION RATES AT THE OTAVALO HOSPITAL: 
In addition to case-finding, effective treatment forms the other half of successful 
TB control policy. Overall cure rates for most national control programs in poor 
developing countries remain well below 50%. Patient compliance (completion of 
treatment) is the most important determinant of the cure rate in national tuberculosis 
control programs. The target WHO cure rate for smear-positive patients is 85% in 
developing countries and 95% in industrialized countries. 
Official statistics for Ecuador as a whole (see Figure 4, page 9) suggest that 20% 
of TB patients abandon treatment nationally. In this retrospective study of patients 
treated at this small hospital in Otavalo over a five-year period, a minimum of 42.2% of 
patients abandoned treatment prior to completing six-months of triple antibiotic 
chemotherapy. An unknown number of patients may have picked up their medication 
regularly but still failed to ingest them as prescribed. Due to the lack of directly observed 
therapy, the percentage of patients who did not properly complete their treatment 
regimens may be significantly higher than the figure (42.2%) cited above, since an 
unknown number of patients who picked up their medication may not have ingested them 
at all, may have taken them incorrectly, or may have ingested them only sporadically. 
Unfortunately, no other similar data has been published in Ecuador to provide a reference 
for these results. 
Nonetheless, this information indicates that a maximum of 57.8% of patients 
completed treatment, and the actual value is certainly significantly lower for the reasons 
mentioned above. Tuberculosis is likely to remain an increasingly difficult problem in 
Ecuador, because it is commonly believed that treatment completion rates of at least 70- 
o c 
85% are necessary to initiate a decline in the incidence of tuberculosis. 
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RISK FACTORS ASSOCIATED WITH NON-COMPLETION OF TREATMENT: 
Three general factors can interfere with a patient's adherence to therapy: patient 
factors, healthcare provider factors, and institutional factors relating to the hospital or 
clinic. Patient factors include the belief that treatment completion is important, and 
understanding of what is necessary to complete treatment, successful integration of the 
medical regimen into daily activities, community and family support for completion of 
treatment, the perceived benefits of treatment, a sense of control and empowerment, the 
duration of treatment, the number of pills taken daily, cost, side-effects, and overcoming 
the negative stigma of TB disease. 
Health care provider related factors include the degree to which a physician or 
other health care worker assumes responsibility for treatment completion, for patient 
education, for monitoring patient adherence (including systems to identify non- 
compliance), and the ability to employ simpler and shorter treatment regimens in patient 
treatment. 
Institutional factors include the accessibility of the clinic in terms of distance from 
the patient, the cost and ease of travel, convenient hours of operation, and a pleasant 
hospital environment including short waiting times, culturally and linguistically 
appropriate treatment, positive staff attitudes and clinical setting, and the use of 
incentives such as child care, food, transportation, livestock, seeds, information, and 
money.86 
TB control programs may fail due to unsuccessful case-finding, poor treatment, or 
both. TB control programs can be impeded by poor implementation of available health 
services, which require reliable microscopic and diagnostic services, a high cure rate and 
strong hospital reputation to attract patients from remote areas, public education to 
encourage symptomatic patients to seek medical advice, culturally and linguistically 
appropriate medical services, well-trained medical staff, convenient hours, reliable 
transport of patient or sputum sample to microscopy and X-ray services (if available), the 
use of financial aid and other incentives (in addition to free treatment) to attract patients 
and retain them in treatment, an uninterrupted supply of antitubercular medication, 
convenient service, a strong doctor/patient relationship, and aggressive home follow-up 
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and outreach by trained community/village-based health workers which make diagnostic 
and treatment services accessible to patients. 
In this retrospective study of 192 patients at the Hospital "San Luis" of Otavalo, I 
hypothesized that there might exist a significant association between non-completion of 
tuberculosis chemotherapy and some of the following six variables: patient age, patient 
gender, distance from patient residence to the hospital, patient diagnosis (pulmonary or 
extrapulmonary TB), and residence in the mountains over 3000 meters. 
In this study of 192 patients, those diagnosed with "non-confirmed" pulmonary 
disease were over 40% more likely to abandon treatment than those with "confirmed" 
pulmonary TB (50.0% of non-confirmed patients abandoned treatment while only 36.6% 
of confirmed patients did so). It may be that when patients receive laboratory 
confirmation and are confident that their diagnosis of pulmonary tuberculosis is correct, 
they may be more likely to endure the inconvenience and discomfort involved in 
complying with antibiotic therapy. 
In this study, men outnumbered women almost two to one (123 patients were 
male while 69 were female). The preponderance of men in this sample may reflect the 
documented high rate of alcoholism among men in this region, or some other factor 
predisposing men to poor general health, malnutrition, and susceptibility to developing 
active TB disease. On the other hand, men may not be more likely to suffer from 
tuberculosis, but rather more likely or more able to seek medical treatment. Women are 
frequently burdened with responsibility for tending the family crops, livestock, and many 
children, and may have significant difficulty in traveling to the provincial hospital to seek 
treatment. In addition, the stigma associated with a diagnosis of tuberculosis can prevent 
many patients from seeking treatment, and patients (especially women) have been 
rejected by their families after being diagnosed with tuberculosis (even non-contagious 
extrapulmonary forms). 
The average patient age in this study was 35.15 (+/- 18.52) years with female 
patients on average 2.61 years older upon beginning treatment than male patients. 
However, this difference between male and female patients was not significant. The 
mean distance between patients' home and the hospital in Otavalo was 9.89 (+/- 11.47) 
kilometers with women living an average of 2.70 kilometers farther from the hospital. 
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Once again, there was no statistically significant difference in the mean distances 
between male and female patients. 
The majority (57.9%) of patients diagnosed and starting antitubercular 
chemotherapy lived in the hard-to-access mountains above 3000 meters. In rural 
Ecuador, with increasing altitude, roads and public transportation become increasingly 
poor. One might expect to find few patients presenting at the hospital from the 
mountains above 3000 meters, but this was not the case. In addition, the urban centers 
and the population in general are concentrated in the valleys below 2500 meters 
(including the town of Otavalo, Ibarra, and Cotacachi), and only a relatively small 
minority of local residents live above 3000 meters. Nonetheless, the majority of patients 
initiating treatment for tuberculosis at the HSLO during this five-year period lived above 
3000 meters. 
In Imbabura province and similar regions of the Andean highlands, inhabitants 
with the fewest vocational skills and socio-economic resources frequently inhabit the 
relatively hostile and infertile terrain found at high-altitude. Elevation in Imbabura 
province ranges from about 2,000 meters (6,600 feet) to 6,000 meters (19,800 feet) above 
sea level. The highest elevations (above approximately 15,000 feet) are essentially 
uninhabitable by humans. The most valuable and productive land lies at low elevation in 
the valleys and the environment above 3,500 meters is characterized by steep, volcanic 
slopes whose soil exhibits poor water-retention and supports little vegetation. The 
climate is significantly colder and damper than at lower elevations, and cultivation of 
agriculture and livestock is difficult and restricted. Both income and infrastructure 
(including roads, electricity, running water, latrines, etc.) are inversely related to altitude. 
The indigenous, Quechua-speaking population of the highlands is one of the poorest 
demographic groups in Ecuador and extreme poverty may, in part, explain a higher 
incidence of tuberculosis in this community. Unfortunately, in this case, the population 
most in need of effective TB diagnosis and treatment is located the farthest away from 
medical resources and, being difficult to reach, can be overlooked or neglected. 
Those patients who abandoned treatment tended to be older, live farther from the 
hospital, have a history of prior treatment for TB, and live in the mountains over 3000 
meters. Patients who abandoned treatment were an average of 6.0 years older. The 

42 
relationship between age and tuberculosis may have underlying biological bases, but may 
also be due to extrinsic social factors that influence the risk of infection and general 
health of the patient. 
Patients who did not complete treatment lived an average of 5.9 kilometers 
farther from the hospital, were 3.03 times as likely to have a history of prior TB 
treatment, and 1.96 times as likely to live in the mountains above 3000 meters when 
compared to patients who completed treatment. There was no significant relationship 
between treatment completion and patient gender or patient diagnosis (i.e. pulmonary 
versus extrapulmonary TB). 
It is possible that patients who lived farther from the hospital encountered more 
economic barriers (transportation costs, the opportunity cost of time lost in transit, etc) in 
regular travel to the hospital to pick up their medication. Similarly, patients residing in 
hard-to-reach mountains above 3000 meters poorly served by local infrastructure and 
public transportation may encounter barriers to weekly travel. The outpatient clinic 
which dispensed medication to these patients maintained limited hours. Residents of 
Imbabura province are not wealthy, and the outpatient clinic is only open during the 
typical work day when many individuals may have difficulty securing the time-off from 
their employment to visit the hospital one afternoon each week. 
Of the 192 patients in the study group, the patient’s address was known in 177 
cases (93%). Two patients were migrant workers from the Republic of Colombia (which 
borders Ecuador to the north), and the remaining patients lived in the province of 
Imbabura. Patients traveled from 39 different townships surrounding Otavalo, whose 
names reflect the mixture of Spanish (i.e. “San Rafael”) and Quechua (i.e. 
“Quinchinche”) language that typifies the linguistic and cultural mixture of the Andean 
highlands. 
Those patients with a history of prior treatment for TB also had a statistically 
significant tendency to abandon treatment. Having already abandoned treatment in the 
past, this may be a form of selecting for patients who are less interested in adhering to the 
Western model of medical treatment, less motivated to complete six months of antibiotic 
treatment, less educated about the potential ramifications of abandoning treatment 
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prematurely, or less financially or logistically capable of weekly travel to Otavalo to pick 
up their medications. 
Only a small minority (6.8%) of patients in this study received treatment for 
extrapulmonary TB. This figure does not necessarily indicate the incidence of 
extrapulmonary tuberculosis relative to pulmonary tuberculosis in this patient population. 
Patients with pulmonary TB may be more likely to seek medical attention, the signs and 
symptoms of pulmonary TB may be more easily recognized by patients and members of 
the community, and patients presenting with pulmonary symptoms may be more easily 
recognized and correctly diagnosed by hospital staff than patients with forms of 
extrapulmonary tuberculosis that are more difficult to diagnose. 
The treatment regimen employed at the Hospital "San Luis" lasted for a total 
duration of six months. This regimen used only three different antitubercular drugs, and 
did not employ combination tablets. In additional, treatment was not directly supervised, 
monitoring of treatment was not aggressive and did not incorporate home visits, and only 
one week's worth of medication was dispensed at a time making treatment inconvenient 
and costly (in terms of time and stress), especially given the poor public transportation 
infrastructure. 
Long durations of treatment adversely affect patient compliance, and short course 
(6 to 8 month) treatment regimens which employ more expensive drugs are generally 
recommended. Economically, short-course therapy (which costs US$40 per patient) is 
more cost-effective than standard 12-month therapy (which costs US$15 per patient) 
because short-course regimens lead to better patient compliance, reduce the number of 
patients in treatment at any one time, and achieve a higher cure rate while also preventing 
the emergence of drug resistant disease (especially when combined isoniazid/rifampicin 
tablets are used). In addition, short course regimens are more likely to benefit patients 
who do not complete the entire regimen. For instance, 90% of patients who complete 
two months of short course treatment convert from smear-positive to smear-negative, 
while only 50% of patients who complete the same two months of standard 12-month 
• 87 treatment convert to smear-negative status. 
The quality of treatment supervision is a major determinant in treatment 
completion rates in any program. A broad possible policy spectrum exists ranging from 
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dispensing a supply of TB drugs for many months, to hospitalizing patients for direct 
supervision for the entire duration of treatment. Many intermediate strategies exist, 
involving daily patient visits to clinics, outreach workers visiting patients in the home or 
workplace, random urine tests to monitor compliance, and treatment as inpatients for 
some fraction of the total treatment duration. Inpatient treatment for two months using a 
short course regimen is recommended in some settings since this direct supervision often 
guarantees sputum conversion in about 90% of cases. 
The final factor determining treatment success is drug resistance. Resistance to 
o o 
isoniazid is already a major problem in many developing nations. Short course drug 
regimens employing four drugs during the two-month intensive phase (i.e. streptomycin, 
isoniazid, rifampicin, and pyrazinamide) virtually prohibit the selection of mycobacteria 
resistant to all four drugs, provided that the initial phase is indeed closely supervised. 
Decreased selection of drug resistant bacteria means that short course regimens are 
significantly more effective long term strategies than standard 12-month treatment 
programs. It is important to stress that simultaneous resistance to rifampicin and 
isoniazid results in TB disease that is effectively incurable in developing countries, with 
OQ 
extremely serious epidemiologic implications in those settings. 
Adherence to the target coverage rate of 70% and cure rate of 85% under the 
World Health Organization's new global TB strategy hopes to save a projected 1.2 
million lives, and reduce the annual TB death rate by 40% — from 2.9 million annually to 
1.7 million deaths annually. In order to achieve this ambitious goal, many developing 
nations in particular will have to devote significantly more resources to improving their 
national TB control programs, focusing on human resource training at many levels and 
making tuberculosis control a serious priority in international health. 
Some significant limitations of this epidemiologic study must be addressed. First, 
HSLO records did not indicate whether or not patients received additional treatment for 
TB at another healthcare facility. An unknown number of patients who apparently 
abandoned treatment may simply have discontinued treatment at the HSLO and 
completed their treatment regimen at another hospital. Secondly, local medical staff 
raised the possibility that some patient records may have been lost or transferred to other 
institutions. This potential source of detection bias, while not quantifiable, must be 
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recognized. Third, since hospital protocol defined those patients who "abandoned 
treatment" as those who failed to pick-up their medication for four consecutive weeks 
(see Methods), it would be possible for a patient to show up only every three weeks and 
still be considered to have completed treatment— having consumed, at most, one-third of 
their medication. Lastly, since both non-confirmed pulmonary TB and extrapulmonary 
TB were both based exclusively on clinical judgement, there may be some overlap 
between these two diagnostic groups. These limitations may have significant effects on 
the validity and interpretation of the above results. 
... 
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STRATEGIES FOR IMPROVING TB CONTROL AT THE OTAVALO HOSPITAL: 
Based on this study, cost-effective recommendations for improving TB control in 
Imbabura province— taking into consideration limited economic and medical resources 
typical of developing countries— include: 
1. Promoting prompt clinical evaluation of patients with respiratory complaints, 
including more consistent use of sputum smear analysis to diagnosis tuberculosis. 
For instance, community outreach programs could be placed in locations that 
patients naturally congregate, including the five local churches, the two local 
markets, and the pharmacies that serve this patient population. These sites could 
provide education, and diagnostic and therapeutic services without requiring 
patients to travel to the hospital. However, due to the significant negative stigma 
associated with TB disease, such outreach programs would have to strictly 
guarantee patient privacy to successfully attract patients and form an effective 
component of the healthcare delivery system. In addition, healthcare workers 
should be provided with protective masks to alleviate their fear of eliciting a 
sputum sample from patients with suspected TB. 
2. Using sputum culture and sensitivity testing when drug-resistant disease is 
suspected (i.e. in patients with multiple past treatment failures). This would 
identify patients with drug-resistant disease, specify those drugs to which local 
patients are developing resistance, and document the extent of (multi)-drug 
resistance in the community. Sputum culture and sensitivity testing are performed 
in Quito (three hours by car from Otavalo). No mechanism currently exists to 
transport samples to Quito, but perhaps transport could be arranged using the local 
buses that travel frequently between these two cities or via motorcycle transport. 
3. Improve the management and supervision of health care workers at the Hospital 
"San Luis" of Otavalo. Health care and laboratory personnel could benefit from 
education in patient care and laboratory diagnostics, and incentives could be 
employed to promote enthusiasm, cooperation, and innovation on the part of 
personnel involved in TB control. As an example, the laboratory at the HSLO 
only accepts sputum samples from patients or staff between 9am and 10am, 
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Monday through Friday. Such unnecessary restrictions interfere with tuberculosis 
control at this hospital. 
4. Without widespread sensitivity testing and considering the high rate of treatment 
non-completion at this hospital, a four-drug regimen (i.e. isoniazid, rifampicin, 
pyrazinamide, and ethambutol) may be more cost-effective and successful than the 
currently used three-drug regimen. Perhaps the WHO or International Union of 
TB and Lung Disease could be petitioned to help finance the acquisition of these 
medications. Care must be taken to maintain a regular and continuous supply of 
anti-tubercular medications at the hospital. 
5. Larger quantities of TB medication (i.e. for two-weeks, or a month— instead of 
only one week) could be distributed to patients upon each visit. Given the poor 
infrastructure and public transportation of Imbabura province, the present policy 
requiring patients to travel to the hospital each week causes unnecessary patient 
inconvenience and expense. Once again, hospital staff should consider taking 
advantage of the local infrastructure (i.e. delivering medications to patients at 
churches, markets, pharmacies, etc.) to maximize results with limited financial 
resources. In addition, patients should be observed taking their medication when 
they present to these settings. However, it is possible that less frequent patient 
contact— while facilitating the distribution of medications— may have deleterious 
effects on patient compliance. 
6. The cultural gap between Quechua-speaking patients and Spanish-speaking health 
care personnel must be addressed. Including more Quechua-speaking health care 
professionals at the hospital in Otavalo, providing cultural training, and improved 
cooperation between hospital staff and traditional, non-Westem health-care 
providers (such as local "curanderos") may make the Hospital "San Luis" more 
acceptable to indigenous, Quechua-speaking patients who become ill and seek 
medical treatment. Some communities have attempted to establish DOT programs 
by including respected local community leaders or patient's family members as 
field supervisors. This approach may help bridge the cultural gap between the 
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Quechua-speaking patients and the Spanish-language healthcare delivery system, 
and promote patient compliance. 
7. The use of economic incentives may help to motivate patients to remain in TB 
treatment. As extreme poverty poses a very serious problem for many local TB 
patients, food, clothing, livestock, seeds, or other basic items could be used as 
incentives to encourage patients to keep picking up their medication at the hospital 
or other convenient location. Of course, in the absence of directly observed 
therapy (DOT), the risk remains that patients will not correctly ingest these 
medications. 
8. Finally, an extensive body of literature indicates that a widespread program of 
directly observed therapy would be ideal. However, financial limitations and 
feasibility issues suggest that a widespread program of DOT will be difficult to 
implement in the immediate future in this environment. However, outreach 
programs (perhaps using motorcycles in this rugged, mountainous terrain) could be 
used to obtain sputum samples from contacts of infectious individuals, locate 
patients who were lost to follow-up prior to completing TB treatment at the 
hospital, and implement a limited program of directly observed therapy. In sum, 
more funds must be allocated to encourage DOT programs, especially in the 
developing nations which suffer the majority of the worldwide tuberculosis disease 
burden. 

1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
49 
REFERENCE NOTES 
Center for Disease Control Morbidity and Mortality Weekly Report. Volume 494, p. 443-4. 
White GL, Henthome BH, Barnes E, Segarra JT. Tuberculosis: A Health Education Imperative 
Returns. Journal of Community Health. Vol. 20, No. 1, p. 29-57, February 1995. 
Murray CJ; Lopez AD . Mortality by Cause for Eight Regions of the World: Global Burden of 
Disease Study. Lancet. May 3,1997; 349(9061): p. 1269-76. 
National Jewish Medical and Research Center. Internet site: gruener.jordan@nijc.org. Denver, 
Colorado. 1996. 
Bayer R, Dupuis L. Tuberculosis, Public Health, and Civil Liberties. Annu. Rev. Public Health. 
Vol. 16, 1995, p. 307-326. 
Bass J, Farer L, Hopewell P, Jacobs R, Miller B, Nardell E, Ruben F, Snider D, Thornton G. 
Control of Tuberculosis in the United States. American Review of Respiratory Disease. Vol. 146, 
No. 6, December 1992, p. 1623-1633. 
Isselbacher, Braunwald. Harrison’s Principles of Internal Medicine. McGraw-Hill, Inc. New 
York. Thirteenth Edition. 1994. 
Bradley K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, 
homelessness, and the decline of tuberculosis control programs. Am. Rev. Resp. Dis. Vol. 144, 
1991, p. 745-749. 
Wolf L. A Tuberculosis Control Plan for Ambulatory Care Centers. Nurse Practitioner. Vol. 20, 
No. 6. p. 34-40. June 1995. 
Bass J, Farer L, Hopewell P, Jacobs R, Miller B, Nardell E, Ruben F, Snider D, Thornton G. 
Control of Tuberculosis in the United States. American Review of Respiratory’ Disease. Vol. 146, 
No. 6, December 1992, p. 1623-1633. 
Brennan B. Facts and figures: Tuberculosis in Latin America and the Caribbean. PAHO. WHO. 
Washington, D.C., March 1996. Internet: http://www.paho.org. 
Manual de Normas Technicas, Metodos y Procedimientos para el Control de la Tuberculosis. 
Programa Nacional de Control de la Tuberculosis. Ministerio de Salud Publica, Republica del 
Ecuador. 1989 
Ministry of Public Health. National Direction of Epidemiology. Quito, Ecuador. 
Arcos, L. La Tuberculosis en el Ecuador, Especialmente en Quito. Biopatologia Andina y 
Tropical Ecuatoriana. Academia Ecuatoriana de Medicina. Quito, Ecuador. First Edition. 1995, 
p. 1343-1355. 
Facts and Figures- Tuberculosis in Latin America and the Caribbean. Pan American Health 
Organization. World Health Organization. March 1996. 
Personal communication with Dr. Juan Vaca and Dr. Luis Flor, among others. 
Houston S, Fanning A. “Current and potential treatment of tuberculosis,” Drugs. 48 (5), p. 689- 
708,1994. 
Facts and Figures- Tuberculosis in Latin America and the Caribbean. Pan American Health 
Organization. World Health Organization. March 1996. 
1994 Population Estimate. Pan American Health Organization (PAHO). 
* 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
50 
Indicadores Basicos 1996— Situacion de Salud en las Americas, Programa Analisis de Situacion 
de Salud, Division de Salud y Desarrollo Humano, Pan American Health Organization (PAHO), 
World Health Organization (WHO), 1996. 
Las Condiciones de Salud en las Americas. PAHO Scientific Publications # 549, Vol. I, 1994, p. 
176-188. 
Las Condiciones de Salud en las Americas. PAHO Scientific Publications # 549, Vol. I, 1994, p. 
176-188. 
Indicadores Basicos 1996— Situacion de Salud en las Americas, Programa Analisis de Situacion 
de Salud, Division de Salud y Desarrollo Humano, Pan American Health Organization (PAHO), 
World Health Organization (WHO), 1996. 
Las Condiciones de Salud en las Americas. PAHO Scientific Publications # 549, Vol. I, 1994, p. 
188. 
Write R, Callanaupa N. Quechua Phrasebook. Lonely Planet Publications. Victoria, Australia, 
1989. 
Write R, Callanaupa N. Quechua Phrasebook. Lonely Planet Publications. Victoria, Australia, 
1989. 
Personal communication with Dr. Luis Flor, Director of Epidemiology. Ministry of Public Health. 
Anuario de Estadisticas Vitales. Volume 21, p. 121-4, 1992. 
Selwyn PA. Tuberculosis and AIDS: epidemiologic, clinical, and social dimensions. JLaw Med. 
Ethics. Vol. 21, 1993, p. 303-316. 
Perfil Socio-Demografico Provincial Imbabura. Centro de Estudios de Poblacion y Patemidad 
Responsable. Quito, Ecuador. Febrero, 1993. 
Incidence de Mycobacterium Tuberculosis en Muestras de Esputo en Pobladores de las 
Comunidades Indigenas de Imbabura. Revista de la Pontificia Universidad Catolica del Ecuador. 
Quito, Ecuador. 1996. 
Indicadores Basicos 1996— Situacion de Salud en las Americas, Programa Analisis de Situacion 
de Salud, Division de Salud y Desarrollo Humano, Pan American Health Organization (PAHO), 
World Health Organization (WHO), 1996. 
PAHO— Technical Information— Country Health Profiles, 1995. 
Perfil Socio-Demografico Provincial Imbabura. Centro de Estudios de Poblacion y Patemidad 
Responsable. Quito, Ecuador. Febrero, 1993. 
Perfil Socio-Demografico Provincial Imbabura. Centro de Estudios de Poblacion y Patemidad 
Responsable. Quito, Ecuador. Febrero, 1993. 
Flor L. Panorama Epidemiologico del Ecuador. Direcion Nacional de Epidemiologia. Quito, 
Ecuador. 1996. 
Zeneida S, Ayolanda V, Graciela R, Mercedes C. Prevalencia de Sintomaticos Respiratorios en 
los Pacientes que Acuden al Centro de Salud de Ibarra. Revista de la Universidad Technica del 
Norte. Facultad de Ciencias de la Salud. Ibarra, Ecuador. 1992, p.43. 
Perfil Socio-Demografico Provincial Imbabura. Centro de Estudios de Poblacion y Patemidad 
Responsable. Quito, Ecuador. Febrero, 1993. 
Acosta M, Gonzalez C, Guevara P. Medicina y Salud en Otavalo. Revista de la Pontificia 
Universidad Catolica de! Ecuador. Facultad de Enfermeria. Quito. Febrero 1985. 
Acosta M, Gonzalez C, Guevara P. Medicina y Salud en Otavalo. Revista de la Pontificia 
Universidad Catolica del Ecuador. Facultad de Enfermeria. Quito. Febrero 1985. 

41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
51 
Indicadores Basicos 1996— Situacion de Salud en las Americas, Programa Analisis de Situacion 
de Salud, Division de Salud y Desarrollo Humano, Pan American Health Organization (PAHO), 
World Health Organization (WHO), 1996. 
Anuario de Estadisticas Vitales, Nacimientos y Defunciones. Institute Nacional de Estadistica y 
Censos. Quito, Ecuador. 1993, p. 424. 
Acosta M, Gonzalez C, Guevara P. Medicina y Salud en Otavalo. Revista de la Pontificia 
Universidad Catolica del Ecuador. Facultad de Enfermeria. Quito. Febrero 1985. 
Wolf L. A Tuberculosis Control Plan for Ambulatory Care Centers. Nurse Practitioner. Vol. 20, 
No. 6. p. 34-40. June 1995. 
Facts and Figures— Tuberculosis in Fatin America and the Caribbean. Pan American Health 
Organization. World Health Organization. March 1996. 
Isselbacher, Braunwald. Harrison’s Principles of Internal Medicine. McGraw-Hill, Inc. New 
York. Thirteenth Edition. 1994. 
Center for Disease Control: Initial therapy for tuberculosis in the era of multidrug resistance. 
MMWR, 1993: 42: 1-8. 
Morbidity and Mortality Weekly Report Supplement. A Strategic Plan for the_Elimination of 
Tuberculosis in the United States. Center for Disease Control. Atlanta, Georgia. Volume 38. 
No. S-3. April 21, 1989. 
Facts and Figures- Tuberculosis in Latin America and the Caribbean. Pan American Health 
Organization. World Health Organization. March 1996. 
Pitchenik AE. Tuberculosis Control and the AIDS Epidemic in Developing Countries. Annals of 
Internal Medicine. Volume 113, Number 2, July 1990, p. 89-91. 
Indicadores Basicos 1996— Situacion de Salud en las Americas, Programa Analisis de Situacion 
de Salud, Division de Salud y Desarrollo Humano, Pan American Health Organization (PAHO), 
World Health Organization (WHO), 1996. 
Isselbacher, Braunwald. Harrison’s Principles of Internal Medicine. McGraw-Hill, Inc. New 
York. Thirteenth Edition. 1994. 
Isselbacher, Braunwald. Harrison’s Principles of Internal Medicine. McGraw-Hill, Inc. New 
York. Thirteenth Edition. 1994. 
Indicadores Basicos 1996— Situacion de Salud en las Americas, Programa Analisis de Situacion 
de Salud, Division de Salud y Desarrollo Humano, Pan American Health Organization (PAHO), 
World Health Organization (WHO), 1996. 
Bass J, Farer L, Hopewell P, Jacobs R, Miller B, Nardell E, Ruben F, Snider D, Thornton G. 
Control of Tuberculosis in the United States. American Review of Respiratory Disease. Vol. 146, 
No. 6, December 1992, p. 1623-1633. 
Manual de Normas Technicas, Metodos y Procedimientos para el Control de la Tuberculosis. 
Programa Nacional de Control de la Tuberculosis. Ministerio de Salud Publica, Republica del 
Ecuador. 1989. 
Office of Technology Assessment United States Congress: The Continuing Challenge of 
Tuberculosis. 1993. OTH-H-574. 
Isselbacher, Braunwald. Harrison’s Principles of Internal Medicine. McGraw-Hill, Inc. New 
York. Thirteenth Edition. 1994. 
Meneses R, Esperanza R, Rojas R, Pozo F. La Efectividad del Tratamiento de Tuberculosis entre 
junio de 1988 y junio de 1989. Revista de la Universidad Technica del Norte. Facultad de 
Ciencias de la Salud. Escuela de Enfermeria. Ibarra, 1991, p.82. 

60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
52 
Sbarbaro JA. Public health aspects of tuberculosis: supervision of therapy. Clin Chest Med, Vol. 
1, 1980, p. 253-263. 
Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven Years of Community-Based Directly 
Observed Therapy for Tuberculosis. Journal of the American Medical Association. Vol. 274, No. 
12, September 27, 1995. p. 945-951. 
Etkind S. The Role of the Public Health Department in Tuberculosis. Medical Clinics of North 
America. Vol. 77, No. 1, November 1993, p. 1303-1314. 
Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City: turning 
the tide. New England Journal of Medicine. Vol. 333, 1995, p. 229-233. 
Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney B, Gomez E, Foresman BH. The effect 
of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. New 
England Journal of Medicine. Vol. 330, No. 17, April 29, 1994, p. 1179-1184. 
Flor L. Panorama Epidemiologico del Ecuador. Direcion Nacional de Epidemiologia. Quito, 
Ecuador. 1996. 
Flor L. Panorama Epidemiologico del Ecuador. Direcion Nacional de Epidemiologia. Quito, 
Ecuador. 1996. 
Falconi, Margarita Ruiz. Explicacion de las Causas de Desercion al Tratamiento, Tuberculosis 
Pulmonar. Hospital Policlinico. Riobamba. 1995. Revista de la Pontificia Universidad Catolica 
del Ecuador. Facultad de Enfermeria. Quito, 1996. 
Arcos, L. La Tuberculosis en el Ecuador, Especialmente en Quito. Biopatologia Andina y 
Tropical Ecuatoriana. Academia Ecuatoriana de Medicina. Quito, Ecuador. First Edition. 1995, 
p. 1343-1355. 
Iseman MD. Treatment of multidrug-resistant tuberculosis. New England Journal of Medicine. 
Vol. 329, No. 11, September 9, 1993. p. 784-791. 
Iseman MD. Treatment of multidrug-resistant tuberculosis. New England Journal of Medicine. 
Vol. 329, No. 11, September 9, 1993. p. 784-791. 
Office of Technology Assessment United States Congress: The Continuing Challenge of 
Tuberculosis. 1993. OTH-H-574. 
Informe del Laboratorio de Tuberculosis, Porcentaje de Cultivos Resistentes 1989 - 1993. 
Hospital Vozandes del Oriente, Ecuador, 1994. 
Flor L. Panorama Epidemiologico del Ecuador. Direcion Nacional de Epidemiologia. Quito, 
Ecuador. 1996 
Meneses R, Esperanza R, Rojas R, Pozo F. La Efectividad del Tratamiento de Tuberculosis entre 
Junio de 1988 y Junio de 1989. Revista de la Universidad Technica del Norte. Facultad de 
Ciencias de la Salud. Escuela de Enfermeria. Ibarra, 1991, p.91. 
Zeneida S, Ayolanda V, Graciela R, Mercedes C. Prevalencia de Sintomaticos Respiratorios en 
los Pacientes que Acuden al Centro de Salud de Ibarra. Revista de la Universidad Technica del 
Norte. Facultad de Ciencias de la Salud. Ibarra, Ecuador. 1992, p.48. 
Brennan B. Facts and figures: Tuberculosis in Latin America and the Caribbean. PAHO. WHO. 
Washington, D.C., March 1996. Internet: http://www.paho.org. 
Perfd Socio-Demografico Provincial Imbabura. Centro de Estudios de Poblacion y Patemidad 
Responsable. Quito, Ecuador. February 1993. 
Manual de Normas Technicas, Metodos y Procedimientos para el Control de la Tuberculosis. 
Programa Nacional de Control de la Tuberculosis. Ministerio de Salud Publica, Republica del 
Ecuador. 1989, 

79 
80 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
53 
Kochi A. The global tuberculosis situation an the new control strategy of the World Health 
Organization. Tubercle. 1991 (72), p. 1-6. 
Fanner P, Robin S. Tuberculosis, Poverty, and "Compliance": Lessons from Rural Haiti. 
Seminars in Respiratory Infections, Vol.6, No. 4 (December), 1991: pp 254-260. 
Chum HJ, Styblo K, Van Cleef. Eight-years' experience of the National Tuberculosis and Leprosy 
Programme in Tanzania. IUAT World Conference on Tuberculosis and Respiratory Diseases. 
1987. p. 111-116. 
Kochi A. The global tuberculosis situation an the new control strategy of the World Health 
Organization. Tubercle. 1991 (72), p. 1-6. 
Carrera AP. El Programa de Control de la Tuberculosis en el Ecuador. Revista de la Pontificia 
Universidad Catolica del Ecuador. Quito, 1996 
Sudra P, Kochi A. Tuberculosis: a global overview of the situation today. Bulletin of the World 
Health Organization, 70, 149, 1992. 
Styblo K. How should a tuberculosis control program be evaluated?, unpublished talk at the World 
Congress on Tuberculosis, Bethesda, MD, November 17, 1992. 
Friedman LN. Tuberculosis: Current Concepts and Treatment. CRC Press. London. 1994. 
Murray CJ. Styblo K. Rouillon A. "Tuberculosis in developing countries: burden, intervention, 
and cost." Evolving Health Sector Priorities in Developing Countries. World Bank Publication. 
1991. 
Kleeberg HH, Boshoff MS. A world atlas of initial drug resistance. Report to the Scientific 
Committee on Bacteriology and Immunology of the IUAT. 1980. 
Shimao T. Drug resistance in tuberculosis control. Tubercle, 68 (Supplement): 5-15 (1987). 
Shimao T. Drug resistance in tuberculosis control. Tubercle, 68 (Supplement): 5-15 (1987). 




HARVEY CUSHING / JOHN HAY WHITNEY 
MEDICAL LIBRARY 
MANUSCRIPT THESES 
Unpublished theses submitted for the Master's and Doctor's degrees and 
deposited in the Medical Library are to be used only with due regard to the 
rights of the authors. Bibliographical references may be noted, but passages 
must not be copied without permission of the authors, and without proper credi 
being given in subsequent written or published work. 
This thesis by has been 
used by the following persons, whose signatures attest their acceptance of the 
above restrictions. 
NAME AND ADDRESS DATE 
YALE MEDICAL LIBRARY 
9002 01048 7925 

